Functions of three ubiquitin-conjugating enzyme 2 genes in hepatocellular carcinoma diagnosis and prognosis

Zhang, Chunye; Yang, Ming

doi:10.4254/wjh.v14.i5.956

Cited by 4 publications

(2 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…UBE2C is highly expressed in patients with TP53-mutated HCC, as are UBE2S and UBE2T. The results of this analysis of clinical patient data were confirmed by other experiments ( 91 ). Expression of UBE2S is associated with survival, metastasis and recurrence in patients with HCC and analysis of TCGA data indicated that the OS and DFS time were shorter in patients with high UBE2S expression.…”

Section: Class III E2s In Digestive System Cancerssupporting

confidence: 80%

See 1 more Smart Citation

Ubiquitin‑conjugating enzymes as potential biomarkers and therapeutic targets for digestive system cancers (Review)

Lei

et al. 2023

Oncol Rep

View full text Add to dashboard Cite

Digestive system cancers are the leading cause of cancer-related death worldwide due to their high morbidity and mortality rates. The current treatment methods include surgical treatment, chemotherapy, radiotherapy and endoscopic treatment, and the precisely targeted therapy of digestive system cancers requires to be further studied. The ubiquitin-proteasome system is the main pathway for protein degradation in cells and the ubiquitin-conjugating enzymes (E2s) have a decisive role in the specific selection of target proteins for degradation. The E2s have an important physiological role in digestive system cancers, which is related to the clinical tumor stage, differentiation degree and poor prognosis. Furthermore, they are involved in the physiological processes of digestive system tumor cell proliferation, migration, invasion, stemness, drug resistance and autophagy. In the present article, the progress and achievements of the E2s in gastric cancer, hepatocellular carcinoma, pancreatic cancer, colorectal cancer, intrahepatic cholangiocarcinoma, gallbladder cancer and esophageal squamous cell carcinoma were reviewed, which may provide early screening indicators and reliable therapeutic targets for digestive system cancers.

show abstract

Section: Class III E2s In Digestive System Cancerssupporting

confidence: 80%

“…Both UBE2S and UBE2T belong to the third class of E2s, both of which have a larger role in HCC. By bioinformatics analysis, Zhang and Yang ( 91 ) found that UBE2S, UBE2T and UBE2C are associated with HCC progression. UBE2C is highly expressed in patients with TP53-mutated HCC, as are UBE2S and UBE2T.…”

Section: Class III E2s In Digestive System Cancersmentioning

confidence: 99%

Ubiquitin‑conjugating enzymes as potential biomarkers and therapeutic targets for digestive system cancers (Review)

Lei

et al. 2023

Oncol Rep

View full text Add to dashboard Cite

show abstract

Thymoquinone-loaded self-nano-emulsifying drug delivery system against ischemia/reperfusion injury

Bahloul

Chaabani

Zahra

et al. 2023

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

Ubiquitin-conjugating enzyme E2C (UBE2C) is a prognostic indicator for cholangiocarcinoma

Ong,

Lai,

Sun

et al. 2023

Eur J Med Res

View full text Add to dashboard Cite

Cholangiocarcinoma is the most common malignant bile duct tumor in Southeast Asia. The special location of cholangiocarcinoma leads to it being difficult to diagnose. Currently, the progress in clinical prognosis outcomes remains abysmal owing to the lack of definitive diagnostic criteria. Therefore, uncovering the potential markers for cholangiocarcinoma is a pressing issue. Ubiquitin-conjugating enzyme E2 C (UBE2C) is a critical ubiquitination enzyme; it is involved in the tumorigenesis of various malignancies and affects the patient’s prognosis. However, there is currently no relevant literature to indicate whether UBE2C is related to the clinical survival outcome of cholangiocarcinoma patients. In this report, we mined the published cholangiocarcinoma transcriptome data set (GSE26566), compared it with the ubiquitination-associated gene (GO:0016567), and identified that UBE2C was highly expressed in cholangiocarcinoma tumor tissue. Moreover, high expression of UBE2C was markedly correlated with surgical margin, primary tumor, histological variants, and histological grade. More specifically, high expression of UBE2C was negatively associated with overall survival, disease-specific survival, local recurrence-free survival, and metastasis-free survival in patients with cholangiocarcinoma. Our findings demonstrate that UBE2C may provide a potential therapeutic marker and prognostic factor for cholangiocarcinoma patients.

show abstract

Functions of three ubiquitin-conjugating enzyme 2 genes in hepatocellular carcinoma diagnosis and prognosis

Cited by 4 publications

References 46 publications

Ubiquitin‑conjugating enzymes as potential biomarkers and therapeutic targets for digestive system cancers (Review)

Ubiquitin‑conjugating enzymes as potential biomarkers and therapeutic targets for digestive system cancers (Review)

Thymoquinone-loaded self-nano-emulsifying drug delivery system against ischemia/reperfusion injury

Ubiquitin-conjugating enzyme E2C (UBE2C) is a prognostic indicator for cholangiocarcinoma

Contact Info

Product

Resources

About